Phathom Pharmaceuticals (PHAT) Return on Capital Employed (2019 - 2026)
Phathom Pharmaceuticals' (PHAT) quarterly Return on Capital Employed came in at 61.49% in Q1 2026, up 4772.0% year-on-year from 1.26% in Q1 2025, and up 54.77% on a QoQ basis from 135.96% in Q4 2025.
Phathom Pharmaceuticals (PHAT) Return on Capital Employed (2019 - 2026) Analysis & Trends
Phathom Pharmaceuticals (PHAT) has 8 years of Return on Capital Employed data on file, last reported at 61.49% in Q1 2026.
- On a quarterly basis, Return on Capital Employed rose 4772.0% year-over-year to 61.49% in Q1 2026; TTM through Mar 2026 was 61.49%, a 4772.0% increase from a year earlier, with the FY2025 full-year figure at 85.7%, up 371.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 61.49%, up from 135.96% in the prior quarter.
- Over the last five years, Return on Capital Employed for PHAT reached as high as 58.37% in Q4 2023 and fell as low as 149.12% in Q2 2025.
- Historically, Return on Capital Employed has averaged 96.25% across 5 years, with a median of 93.29% in 2022.
- Across the five-year window, Return on Capital Employed jumped 5697 bps in 2024 and slumped 6223 bps in 2025, its largest moves.
- Year by year, Return on Capital Employed stood at 109.74% in 2022, then jumped by 47 bps to 58.37% in 2023, then tumbled by 60 bps to 93.44% in 2024, then tumbled by 46 bps to 135.96% in 2025, then surged by 55 bps to 61.49% in 2026.
- Per Business Quant data, the three most recent Return on Capital Employed figures were 61.49% in Q1 2026, 135.96% in Q4 2025, and 140.32% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Phathom Pharmaceuticals | 951.79 Mn | 768.02 Mn | 46.31 Mn | -61.49% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -61.49% |
| Dec 31, 2025 | -135.96% |
| Sep 30, 2025 | -140.32% |
| Jun 30, 2025 | -149.12% |
| Mar 31, 2025 | -109.21% |
| Dec 31, 2024 | -93.44% |
| Sep 30, 2024 | -100.00% |
| Jun 30, 2024 | -86.89% |
| Mar 31, 2024 | -60.63% |
| Dec 31, 2023 | -58.37% |
| Sep 30, 2023 | -63.46% |
| Jun 30, 2023 | -82.50% |
| Mar 31, 2023 | -117.61% |
| Dec 31, 2022 | -109.74% |
| Sep 30, 2022 | -85.93% |
| Jun 30, 2022 | -93.29% |
| Mar 31, 2022 | -88.32% |
| Dec 31, 2021 | -71.10% |
| Sep 30, 2021 | -79.77% |
| Jun 30, 2021 | -80.78% |